First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer

被引：0
|
作者：
Hossein Taghizadeh
Matthias Unseld
Andreas Schmiderer
Angela Djanani
Klaus Wilthoner
Dieter Buchinger
Gerald W. Prager
机构：
[1] Medical University of Vienna,Clinical Division of Oncology, Department of Medicine I
[2] Comprehensive Cancer Center,Clinical Division of Gastroenterology, Hepatology and Metabolism, Department of Internal Medicine I
[3] Medical University Innsbruck,Clinical Division of Oncology, Department of Medicine I
[4] Salzkammergut Klinikum,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
Biliary tract cancer; Chemotherapy; Nanoliposomal irinotecan; Progression-free survival; Overall survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：109 / 115
页数：6
相关论文
共 50 条
  • [31] Chronomodulated infusion of irinotecan, 5-fluorouracil and folinic acid and hematological toxicity in patients with advanced gastrointestinal cancer
    Merkel, U
    Farker, K
    Wedding, U
    Hippius, M
    Höffken, K
    Hoffmann, A
    MEDIZINISCHE KLINIK, 2006, 101 (04) : A45 - A45
  • [32] Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer
    Moehler, M
    Haas, U
    Siebler, J
    Schimanski, C
    Hertkorn, C
    Hoehler, T
    Galle, PR
    Heike, M
    ANTI-CANCER DRUGS, 2003, 14 (08) : 645 - 650
  • [33] Biweekly irinotecan plus bolus 5-fluorouracil and folinic acid in patients with advanced stage colorectal cancer
    Yalcin, S
    Oksuzoglu, B
    Tekuzman, G
    Engin, H
    Celik, I
    Turker, A
    Barista, I
    Gullu, I
    Guler, N
    Altundag, K
    Ozisik, Y
    Kars, A
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2003, 33 (11) : 580 - 583
  • [34] Treatment with 5-Fluorouracil/Folinic Acid, Oxaliplatin, and Irinotecan Enables Surgical Resection of Metastases in Patients With Initially Unresectable Metastatic Colorectal Cancer
    Gianluca Masi
    Samanta Cupini
    Lorenzo Marcucci
    Elisa Cerri
    Fotios Loupakis
    Giacomo Allegrini
    Isa Maura Brunetti
    Elisabetta Pfanner
    Maurizio Viti
    Orlando Goletti
    Franco Filipponi
    Alfredo Falcone
    Annals of Surgical Oncology, 2006, 13 : 58 - 65
  • [35] Irinotecan combined with infusional 5-fluorouracil and folinic acid (folfiri) in patients with metastatic gastric cancer resistant to cisplatin-containing chemotherapy
    Fazio, N
    Zampino, G
    Nolè, F
    Lorizzo, K
    Ardito, R
    Manzoni, S
    Rocca, A
    Minchella, I
    De Braud, F
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 349S - 349S
  • [36] 5-FLUOROURACIL WITH FOLINIC ACID IS NOT EFFECTIVE AGAINST METASTATIC ADENOCARCINOMA OF THE LUNG
    EVANS, WK
    SHEPHERD, FA
    STEWART, DJ
    MAROUN, JA
    WIERZBICKI, R
    RUSTHOVEN, J
    AITKEN, SE
    EZZAT, A
    CANCER INVESTIGATION, 1990, 8 (3-4) : 345 - 349
  • [37] Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer
    Masi, G
    Cupini, S
    Marcucci, L
    Cerri, E
    Loupakis, F
    Allegrini, G
    Brunetti, IM
    Pfanner, E
    Viti, M
    Goletti, O
    Filipponi, F
    Falcone, A
    ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (01) : 58 - 65
  • [38] Bimonthly Chemotherapy with Oxaliplatin, Irinotecan, Infusional 5-Fluorouracil/Folinic Acid in Patients with Metastatic Colorectal Cancer Pretreated with Irinotecan- or Oxaliplatin-Based Chemotherapy
    Nobili, S.
    Checcacci, D.
    Filippelli, F.
    Del Buono, S.
    Mazzocchi, V.
    Mazzei, T.
    Mini, E.
    JOURNAL OF CHEMOTHERAPY, 2008, 20 (05) : 622 - 631
  • [39] Chronotherapy with 5-fluorouracil, oxaliplatin, and folinic acid in colorectal cancer
    Sandor, V
    LANCET, 1997, 350 (9087): : 1325 - 1326
  • [40] PROGNOSTIC FACTORS IN PATIENTS WITH METASTATIC COLORECTAL-CANCER RECEIVING 5-FLUOROURACIL AND FOLINIC ACID
    STEINBERG, J
    ERLICHMAN, C
    GADALLA, T
    FINE, S
    WONG, A
    EUROPEAN JOURNAL OF CANCER, 1992, 28A (11) : 1817 - 1820
12345